LDL-C Archives - The Cardiology Advisor

2015 saw a great leap forward in the development and use of PCSK9 (proprotein convertase subtilisin/kexin) inhibitors. This past July, the FDA approved alirocumab (Praluent, Regeneron), followed 1 month later by the approval of a second PCSK9 inhibitor evolocumab (Repatha, Amgen). The drugs were approved for use in addition to diet and maximally tolerated statin therapy in adult patients with heterozygous familial hypercholesterolemia or those with clinical atherosclerotic cardiovascular disease requiring additional LDL-C lowering. A third drug, bococizumab (Pfizer), is currently in development. Data from large, long-term randomized controlled outcomes trials—ODYSSEY Outcomes (alirocumab), FOURIER (evolocumab), and SPIRE (bococizumab)—are anticipated to provide clear answers as to the drugs' impact on cardiovascular events and safety profiles. –from "The Promise of PSCK9 Inhibitors by Brian Ellis,” published 11/9/15.

Dyslipidemia

Expert Q&A: Reassessing Risk-Based LDL-C Targets

By

Tori Rodriguez, MA, LPC, AHC

October 22, 2020

Lipid-lowering therapies are key to the prevention of cardiovascular (CV) events and CV-related mortality.

Dyslipidemia

Cholesterol Monitoring Rates Remain Low Despite 2018 Guideline Updates

By

Michelle Lampariello

October 22, 2020

After lipid monitoring guidelines were updated in 2018 by the AHA/ACC, researchers observed only a modest increase in patients completing lipid panels following statin initiation.

Dyslipidemia

Statin Plus Ezetimibe as Fixed-Dose Combination for LDL-C Reduction in High-Risk Patients

By

Colby Stong

October 15, 2020

A combination of statin and ezetimibe vs statin alone was found to further reduce levels of LDL-C in patients at very high cardiovascular risk.

Dyslipidemia

Adjusting Multimodal Lipid-Lowering Therapy in bi-Allelic Familial Hypercholesterolemia

By

Jessica Nye, PhD

October 8, 2020

Multimodal lipid lowering therapy may be regularly adjusted in patients with bi-allelic familial hypercholesterolemia based on ultrasounds of all accessible arteries.

Dyslipidemia

Alirocumab Found to Consistently Lower LDL-C, Regardless of Baseline BMI

By

Colby Stong

October 5, 2020

Alirocumab was associated with consistent reductions in LDL-C.

Dyslipidemia

Cumulative Exposure to Elevated LDL-C and Future Risk for CVD Events

By

Brandon May

October 2, 2020

The cumulative number of years an individual is exposed to elevated levels of LDL-C may predict the risk for future CVD events.

ATA: Levothyroxine Should Remain Standard of Care for Hypothyroidism

Dyslipidemia

HDL Cholesterol Efflux May Be Impaired in Severe Short-Term Hypothyroidism

By

Amit Akirov, MD

September 21, 2020

High-density lipoprotein cholesterol efflux capacity may be impaired in patients with severe short-term hypothyroidism.

Dyslipidemia

Consistent LDL-C Lowering Reported With Twice-Yearly Inclisiran

By

Brian Park, PharmD

September 14, 2020

The post-hoc analysis included 2 placebo-controlled phase 3 studies (ORION-10 and -11) that evaluated the efficacy and safety of inclisiran sodium in more than 2300 adult patients.

Dyslipidemia

Evinacumab Found to Lower LDL-C in Homozygous Familial Hypercholesterolemia

By

Jessica Nye, PhD

September 9, 2020

The addition of evinacumab to stable lipid-lowering therapy was found to reduce levels of LDL-C in patients with homozygous familial hypercholesterolemia.

Dyslipidemia

Evolocumab Lowers LDL-C in Pediatric Patients With HeFH

By

Brian Park, PharmD

September 4, 2020

The multicenter, double-blind, placebo-controlled HAUSER-RCT study assessed the efficacy and safety of evolocumab in 157 patients aged 10 to 17 years with HeFH.